Notice of Listing of Members of the Food and Drug Administration's Senior Executive Service Performance Review Board, 76980-76981 [2011-31579]
Download as PDF
<![CDATA[
76980
Federal Register / Vol. 76, No. 237 / Friday, December 9, 2011 / Notices
design presented in this notice reflects
only changes suggested by external peer
reviewers and further discussion among
research team members.
FDA estimates the burden of this
collection of information as follows:
TABLE 4—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
responses per
respondent
Number of
respondents
Activity
Total annual
responses
Average burden
per response
Screener ...........................................................
19,120
1
19,120
Pretest ..............................................................
900
1
900
Main Study .......................................................
8,660
1
8,660
Total ..........................................................
............................
............................
............................
1 There
0.03
(2 min.)
0.33
(20 min.)
0.33
(20 min.)
637
300
2,887
............................
3,824
are no capital costs or operating and maintenance costs associated with this collection of information.
IV. References
The following references have been
placed on display in the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852,
and may be seen by interested persons
between 9 a.m. and 4 p.m., Monday
through Friday. (FDA has verified the
Web site addresses, but FDA is not
responsible for any subsequent changes
to the Web sites after this document
publishes in the Federal Register.)
srobinson on DSK4SPTVN1PROD with NOTICES
Total hours
1. Agency for Healthcare Research and
Quality (AHRQ), AHRQ Home Page,
‘‘Fact Sheets on Recovery Act
Investments in Comparative
Effectiveness Research’’ (https://
www.ahrq.gov/fund/cerfactsheets/). Last
accessed May 23, 2011.
2. Ang, S.H. and S.B. Leong, ‘‘Comparative
Advertising: Superiority Despite
Interference?’’ Asia Pacific Journal of
Management, vol. 11, pp. 33–46, 1994.
3. Demirdjian, Z.S., ‘‘Sales Effectiveness of
Comparative Advertising: An
Experimental Field Investigation,’’
Journal of Consumer Research, vol. 10,
pp. 362–364, 1983.
4. Grewal, D., S. Kavanoor, E.F. Fern, et al.,
‘‘Comparative Versus Noncomparative
Advertising: A Meta-Analysis,’’ Journal
of Marketing, vol. 61, pp. 1–15, 1997.
5. Priester, J.R., J. Godek, D.J.
Nayakankuppum, et al., ‘‘Brand
Congruity and Comparative Advertising:
When and Why Comparative
Advertisements Lead to Greater
Elaboration,’’ Journal of Consumer
Psychology, vol. 14, pp. 115–123, 2004.
6. Rogers, J.C. and T.G. Williams,
‘‘Comparative Advertising Effectiveness:
Practitioners’ Perceptions Versus
Academic Research Findings,’’ Journal of
Advertising Research, vol. 29, pp. 22–37,
1989.
7. Miniard, P.W., M.J. Barone, R.L. Rose, et
al., ‘‘A Re-Examination of the Relative
Persuasiveness of Comparative and
Noncomparative Advertising,’’ Advances
in Consumer Research, vol. 21, pp. 299–
303, 1994.
8. Droge, C. and R.Y. Darmon, ‘‘Associative
VerDate Mar<15>2010
18:35 Dec 08, 2011
Jkt 226001
Positioning Strategies Through
Comparative Advertising: Attribute
Versus Overall Similarity Approaches,’’
Journal of Marketing Research, vol. 24,
pp. 377–388, 1987.
9. Gorn, G.J. and C.B.Weinberg, ‘‘The Impact
of Comparative Advertising on
Perception and Attitude: Some Positive
Findings,’’ Journal of Consumer
Research, vol. 11, pp. 719–727, 1984.
10. Iyer, E.S. ‘‘The Influence of Verbal
Content and Relative Newness on the
Effectiveness of Comparative
Advertising,’’ Journal of Advertising, vol.
17, pp. 15–21, 1988.
11. Schwartz, L.M., S. Woloshin, and H.G.
Welch, ‘‘Using a Drug Facts Box to
Communicate Drug Benefits and Harms:
Two Randomized Trials.’’ Annals of
Internal Medicine, vol. 150, pp. 516–527,
2009.
12. Hauber, A.B., A.F. Mohamed, F.R.
Johnson, et al., ‘‘Treatment Preferences
and Medication Adherence of People
With Type 2 Diabetes Using Oral
Glucose-Lowering Agents,’’ Diabetic
Medicine: A Journal of the British
Diabetic Association, vol. 26, pp. 416–
424, 2009.
13. Mitra, A., J. Swasy,, and K. Aikin, ‘‘How
Do Consumers Interpret Market
Leadership Claims in Direct-toConsumer Advertising of Prescription
Drugs?’’ Advances in Consumer
Research, vol. 33, pp. 381–387, 2006.
Dated: December 5, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–31609 Filed 12–8–11; 8:45 am]
BILLING CODE 4160–01–P
PO 00000
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0769]
Notice of Listing of Members of the
Food and Drug Administration’s Senior
Executive Service Performance Review
Board
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is publishing a
list of members who may be named to
serve on FDA’s Senior Executive
Performance Review Board or Panels,
which oversee the evaluation of
performance appraisals of FDA’s Senior
Executive Service (SES) members. The
Civil Service Reform Act of 1978
requires that the appointment of
Performance Review Board Members be
published in the Federal Register.
FOR FURTHER INFORMATION CONTACT:
Mary Wathen, Office of Management
Programs, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 1, rm. 4310, Silver Spring,
MD 20993, (301) 796–8848.
SUPPLEMENTARY INFORMATION: The Civil
Service Reform Act of 1978 (5 U.S.C.
4314(c)(4)) (Public Law 95–454) requires
that the appointment of Performance
Review Board Members be published in
the Federal Register. The following
persons may be named to serve on
FDA’s Performance Review Board or
Panels.
SUMMARY:
SES
Jeanne Anson
Deborah Autor
Jane Axelrad
Lawrence
Bachorik
Glenda Barfell
Frm 00047
Fmt 4703
Sfmt 4703
E:\FR\FM\09DEN1.SGM
09DEN1
Non-SES
Dennis Baker
Norman Baylor
Nega Beru
Gail Costello
Lawrence Deyton
Federal Register / Vol. 76, No. 237 / Friday, December 9, 2011 / Notices
SES
Non-SES
Catherine Beck
Susan Bernard
Malcolm Bertoni
Eric Blumberg
Beverly
Chernaik
Dara Corrigan
Kathleen Crosby
L’Tonya Davis
David Elder
Denise Esposito
Tracy Forfa
Lillian Gill
Deborah Henderson
Kimberly Holden
Jeanne Ireland
Melanie Keller
Michael Landa
Caroline Lewis
Eric Lindblom
Mary Anne Malarkey
Diane Maloney
Daniel
McChesney
William
McConagha
Patrick McGarey
Ruth McKee
Alfred R. Miller
Theresa Mullin
Deanna Murphy
Melinda Plaisier
Lynne Rice
Mark Roh
James Sigg
Steven Silverman
Howard
Sklamberg
Philip Spiller
Nancy Stade
John Taylor
Michael Taylor
Brian Trent
Mary Lou
Valdez
Steven Vaughn
Stephen
Veneruso
Helen Winkle
Ann Wion
Bernadette Dunham
Ted Elkin
Jeff Farrar
William Flynn
Christy Foreman
Malcolm Frazier
Alberto Gutierrez
Sheryl Lard-Whiteford
Murray Lumpkin
William Maisel
Karen Midthun
Ellen Morrison
Steven Musser
Steven Pollack
Jonathan Sackner-Bernstein
Barbara Schneeman
Rachel Sherman
Jeffrey Shuren
Ann Simoneau
William Slikker
Steven Solomon
Stephen Spielberg
Roberta Wagner
David White
Carolyn Wilson
Janet Woodcock
Robert Yetter
Donald Zink
Dated: December 1, 2011.
Margaret A. Hamburg,
Commissioner of Food and Drugs.
[FR Doc. 2011–31579 Filed 12–8–11; 8:45 am]
srobinson on DSK4SPTVN1PROD with NOTICES
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
VerDate Mar<15>2010
18:35 Dec 08, 2011
Jkt 226001
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel, NCI SPORE
in Prostate and Gastrointestinal Cancers.
Date: February 15–16, 2012.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, Montgomery County
Conference Center Facility, 5701 Marinelli
Road, North Bethesda, MD 20852.
Contact Person: Caron A Lyman, PhD,
Scientific Review Officer, National Cancer
Institute, NIH, Division of Extramural
Activities, Research Programs Review
Branch, 6116 Executive Blvd., Room 8119,
Bethesda, MD 20892–8328, (301) 451–4761,
lymanc@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel,
International Tobacco and Health Research
and Capacity Building Program.
Date: February 28–29, 2012.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Gerald G. Lovinger, PhD,
Scientific Review Officer, Special Review
and Logistics Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
6116 Executive Blvd., Room 8055A,
Bethesda, MD 20892–8329, (301) 496–7987,
lovingeg@mail.nih.gov.
Name of Commitee: National Cancer
Institute Special Emphasis Panel, Small
Grants Program for Cancer Epidemiology.
Date: March 22–23, 2012.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, Montgomery County
Conference Center Facility, 5701 Marinelli
Road, North Bethesda, MD 20852.
Contact Person: Jeffrey E. DeClue, PhD,
Scientific Review Officer, Special Review
and Logistics Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
6116 Executive Boulevard, Room 8059,
Bethesda, MD 20892–8329, (301) 496–7904,
decluej@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel,
Nanotechnology Reformulations for Cancer
Drugs.
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
76981
Date: April 12, 2012.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate contract
proposals.
Place: Bethesda North Marriott Hotel &
Conference Center, Montgomery County
Conference Center Facility, 5701 Marinelli
Road, North Bethesda, MD 20852.
Contact Person: Jeffrey E. DeClue, PhD,
Scientific Review Officer, Special Review
and Logistics Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
6116 Executive Boulevard, Room 8059,
Bethesda, MD 20892–8329, (301) 496–7904,
decluej@mail.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/sep/sep.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: December 5, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–31679 Filed 12–8–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
[Docket No. DHS–2011–0115]
Request for Public Comments
Concerning U.S.-Canada Action Plan
for Perimeter Security and Economic
Competitiveness
Office of Policy, DHS.
Notice.
AGENCY:
ACTION:
The United States and Canada
are staunch allies, vital economic
partners, neighbors, and steadfast
friends. We share common values,
communities, and deep links among our
citizens. The extensive mobility of
people, goods, capital, and information
between our two countries has helped
ensure that our societies remain open,
democratic, prosperous, and secure.
On February 4, 2011, President Barack
Obama and Canadian Prime Minister
Stephen Harper announced Beyond the
Border: A Shared Vision for Perimeter
Security and Economic
Competitiveness. This declaration
describes a perimeter approach to
security in which the United States and
Canada share responsibility for the
security and resilience of our nations.
SUMMARY:
E:\FR\FM\09DEN1.SGM
09DEN1
]]>Agencies
[Federal Register Volume 76, Number 237 (Friday, December 9, 2011)]
[Notices]
[Pages 76980-76981]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-31579]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0769]
Notice of Listing of Members of the Food and Drug
Administration's Senior Executive Service Performance Review Board
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is publishing a list of
members who may be named to serve on FDA's Senior Executive Performance
Review Board or Panels, which oversee the evaluation of performance
appraisals of FDA's Senior Executive Service (SES) members. The Civil
Service Reform Act of 1978 requires that the appointment of Performance
Review Board Members be published in the Federal Register.
FOR FURTHER INFORMATION CONTACT: Mary Wathen, Office of Management
Programs, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
1, rm. 4310, Silver Spring, MD 20993, (301) 796-8848.
SUPPLEMENTARY INFORMATION: The Civil Service Reform Act of 1978 (5
U.S.C. 4314(c)(4)) (Public Law 95-454) requires that the appointment of
Performance Review Board Members be published in the Federal Register.
The following persons may be named to serve on FDA's Performance Review
Board or Panels.
------------------------------------------------------------------------
SES Non-SES
------------------------------------------------------------------------
Jeanne Anson Dennis Baker
Deborah Autor Norman Baylor
Jane Axelrad Nega Beru
Lawrence Bachorik Gail Costello
Glenda Barfell Lawrence Deyton
[[Page 76981]]
Catherine Beck Bernadette Dunham
Susan Bernard Ted Elkin
Malcolm Bertoni Jeff Farrar
Eric Blumberg William Flynn
Beverly Chernaik Christy Foreman
Dara Corrigan Malcolm Frazier
Kathleen Crosby Alberto Gutierrez
L'Tonya Davis Sheryl Lard-Whiteford
David Elder Murray Lumpkin
Denise Esposito William Maisel
Tracy Forfa Karen Midthun
Lillian Gill Ellen Morrison
Deborah Henderson Steven Musser
Kimberly Holden Steven Pollack
Jeanne Ireland Jonathan Sackner-Bernstein
Melanie Keller Barbara Schneeman
Michael Landa Rachel Sherman
Caroline Lewis Jeffrey Shuren
Eric Lindblom Ann Simoneau
Mary Anne Malarkey William Slikker
Diane Maloney Steven Solomon
Daniel McChesney Stephen Spielberg
William McConagha Roberta Wagner
Patrick McGarey David White
Ruth McKee Carolyn Wilson
Alfred R. Miller Janet Woodcock
Theresa Mullin Robert Yetter
Deanna Murphy Donald Zink
Melinda Plaisier ...................................
Lynne Rice ...................................
Mark Roh ...................................
James Sigg ...................................
Steven Silverman ...................................
Howard Sklamberg ...................................
Philip Spiller ...................................
Nancy Stade ...................................
John Taylor ...................................
Michael Taylor ...................................
Brian Trent ...................................
Mary Lou Valdez ...................................
Steven Vaughn ...................................
Stephen Veneruso ...................................
Helen Winkle ...................................
Ann Wion ...................................
------------------------------------------------------------------------
Dated: December 1, 2011.
Margaret A. Hamburg,
Commissioner of Food and Drugs.
[FR Doc. 2011-31579 Filed 12-8-11; 8:45 am]
BILLING CODE 4160-01-P
